Free tool
FAERS Monitor: Lexapro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021440 or its brand name (Lexapro, Escitalopram Oxalate). Reports on generic versions are filed under their own applications.
Reports
127,231
Serious
84,617
67% of reports
Hospitalization
39,685
Death reported
10,109
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea8,649
- fatigue8,646
- drug ineffective8,210
- headache6,442
- diarrhoea6,305
- anxiety6,260
- depression5,814
- dizziness5,723
- off label use5,573
- pain5,306
- fall5,050
- vomiting4,742
- dyspnoea4,725
- insomnia4,124
- asthenia4,009
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,788 |
| 2005 | 2,181 |
| 2006 | 2,103 |
| 2007 | 2,484 |
| 2008 | 2,407 |
| 2009 | 3,301 |
| 2010 | 4,363 |
| 2011 | 4,140 |
| 2012 | 4,641 |
| 2013 | 3,839 |
| 2014 | 4,290 |
| 2015 | 6,534 |
| 2016 | 8,096 |
| 2017 | 7,350 |
| 2018 | 8,674 |
| 2019 | 8,985 |
| 2020 | 8,696 |
| 2021 | 7,186 |
| 2022 | 7,544 |
| 2023 | 7,524 |
| 2024 | 7,739 |
| 2025 | 7,551 |
| 2026 | 5,814 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,926,928 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| depressionSignal | 5,814 | 4.3 | 4.2 | 14,549 |
| anxietySignal | 6,260 | 3.7 | 3.6 | 12,200 |
| insomniaSignal | 4,124 | 2.6 | 2.5 | 3,992 |
| fallSignal | 5,050 | 2.5 | 2.5 | 4,681 |
| dizziness | 5,723 | 1.9 | 1.9 | 2,500 |
| fatigue | 8,646 | 1.8 | 1.8 | 3,437 |
| nausea | 8,649 | 1.8 | 1.8 | 3,255 |
| asthenia | 4,009 | 1.8 | 1.7 | 1,354 |
| headache | 6,442 | 1.7 | 1.7 | 1,919 |
| vomiting | 4,742 | 1.7 | 1.6 | 1,303 |
| diarrhoea | 6,305 | 1.6 | 1.6 | 1,531 |
| pain | 5,306 | 1.4 | 1.4 | 705 |
| dyspnoea | 4,725 | 1.4 | 1.3 | 510 |
| off label use | 5,573 | 1.1 | 1.0 | 15 |
| drug ineffective | 8,210 | 1.0 | 1.0 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.